- Home
- Publications
- Publication Search
- Publication Details
Title
Review article: systemic treatment of hepatocellular carcinoma
Authors
Keywords
-
Journal
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
Volume 48, Issue 6, Pages 598-609
Publisher
Wiley
Online
2018-07-24
DOI
10.1111/apt.14913
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Pembrolizumab for metastatic hepatocellular carcinoma following live donor liver transplantation: The silver bullet?
- (2018) Ashwin Rammohan et al. HEPATOLOGY
- Gut Microbes May Shape Response to Cancer Immunotherapy
- (2018) Tracy Hampton JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma
- (2018) Pierce K.H. Chow et al. JOURNAL OF CLINICAL ONCOLOGY
- The impact of combining Selective Internal Radiation Therapy (SIRT) with Sorafenib on overall survival in patients with advanced hepatocellular carcinoma: The Soramic trial palliative cohort
- (2018) J. Ricke et al. JOURNAL OF HEPATOLOGY
- Targets for immunotherapy of liver cancer
- (2018) Tim F. Greten et al. JOURNAL OF HEPATOLOGY
- EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
- (2018) Peter R. Galle et al. JOURNAL OF HEPATOLOGY
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
- (2018) Masatoshi Kudo et al. LANCET
- Hepatocellular carcinoma
- (2018) Alejandro Forner et al. LANCET
- High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy
- (2018) Carsten Krieg et al. NATURE MEDICINE
- Sorafenib response in hepatocellular carcinoma: MicroRNAs as tuning forks
- (2017) Shruthi Kanthaje et al. HEPATOLOGY RESEARCH
- SARAH: a randomised controlled trial comparing efficacy and safety of selective internal radiation therapy (with yttrium-90 microspheres) and sorafenib in patients with locally advanced hepatocellular carcinoma
- (2017) V. Vilgrain et al. JOURNAL OF HEPATOLOGY
- Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma
- (2017) Austin G. Duffy et al. JOURNAL OF HEPATOLOGY
- Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Jordi Bruix et al. LANCET
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
- (2017) Anthony B El-Khoueiry et al. LANCET
- Fatal orthotopic liver transplant organ rejection induced by a checkpoint inhibitor in two patients with refractory, metastatic hepatocellular carcinoma
- (2017) Brian D. Friend et al. PEDIATRIC BLOOD & CANCER
- Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
- (2017) Bertrand Routy et al. SCIENCE
- Targeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapy
- (2017) Matthias Pinter et al. Science Translational Medicine
- Liquid biopsy in patients with hepatocellular carcinoma: Circulating tumor cells and cell-free nucleic acids
- (2017) Wataru Okajima et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Liver cancers with stem/progenitor-cell features – a rare chemotherapy-sensitive malignancy
- (2017) Bruno Christian Köhler et al. Oncotarget
- Liquid Biopsy and Therapeutic Targets: Present and Future Issues in Thoracic Oncology
- (2017) Paul Hofman Cancers
- Immune suppressive mechanisms in the tumor microenvironment
- (2016) David H Munn et al. CURRENT OPINION IN IMMUNOLOGY
- Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma
- (2016) Jordi Bruix et al. GASTROENTEROLOGY
- Variable Intra-Tumor Genomic Heterogeneity of Multiple Lesions in Patients With Hepatocellular Carcinoma
- (2016) Ruidong Xue et al. GASTROENTEROLOGY
- Rationally combining anti-VEGF therapy with checkpoint inhibitors in hepatocellular carcinoma
- (2016) Tai Hato et al. Immunotherapy
- Phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC): CALGB 80802 (Alliance).
- (2016) Ghassan K. Abou-Alfa et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma
- (2016) Kenji Ikeda et al. JOURNAL OF GASTROENTEROLOGY
- Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study
- (2016) Jorge A. Marrero et al. JOURNAL OF HEPATOLOGY
- Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial
- (2016) Riccardo Lencioni et al. JOURNAL OF HEPATOLOGY
- Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy
- (2016) Hong Jiang et al. NATURE MEDICINE
- MicroRNAs for the Prediction of Early Response to Sorafenib Treatment in Human Hepatocellular Carcinoma
- (2016) Naoshi Nishida et al. Liver Cancer
- Personalized Clinical Trials in Hepatocellular Carcinoma Based on Biomarker Selection
- (2016) Bingnan Zhang et al. Liver Cancer
- Global cancer statistics, 2012
- (2015) Lindsey A. Torre et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Immunotherapy in hepatocellular carcinoma: Primed to make a difference?
- (2015) James J. Harding et al. CANCER
- Current concepts of immune based treatments for patients with HCC: from basic science to novel treatment approaches
- (2015) Tim F Greten et al. GUT
- CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice
- (2015) Yunching Chen et al. HEPATOLOGY
- Pattern of tumor progression in liver cancer: The missing partner in trial design
- (2015) Maria Reig et al. HEPATOLOGY
- SEARCH: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Sorafenib Plus Erlotinib in Patients With Advanced Hepatocellular Carcinoma
- (2015) Andrew X. Zhu et al. JOURNAL OF CLINICAL ONCOLOGY
- Linifanib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized Phase III Trial
- (2015) Calin Cainap et al. JOURNAL OF CLINICAL ONCOLOGY
- Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial
- (2015) Andrew X Zhu et al. LANCET ONCOLOGY
- Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial
- (2015) Jordi Bruix et al. LANCET ONCOLOGY
- Combination cancer immunotherapies tailored to the tumour microenvironment
- (2015) Mark J. Smyth et al. Nature Reviews Clinical Oncology
- Immunological landscape and immunotherapy of hepatocellular carcinoma
- (2015) Jesús Prieto et al. Nature Reviews Gastroenterology & Hepatology
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- MicroRNA-423-5p Promotes Autophagy in Cancer Cells and Is Increased in Serum From Hepatocarcinoma Patients Treated With Sorafenib
- (2015) Paola Stiuso et al. Molecular Therapy-Nucleic Acids
- Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia
- (2014) Rakesh K. Jain CANCER CELL
- A Phase II Study of the Efficacy and Safety of the Combination Therapy of the MEK Inhibitor Refametinib (BAY 86-9766) Plus Sorafenib for Asian Patients with Unresectable Hepatocellular Carcinoma
- (2014) H. Y. Lim et al. CLINICAL CANCER RESEARCH
- Hepatocellular Carcinoma: Reasons for Phase III Failure and Novel Perspectives on Trial Design
- (2014) J. M. Llovet et al. CLINICAL CANCER RESEARCH
- Epidemiological Trends of Hepatocellular Carcinoma in Austria
- (2014) Matthias Pinter et al. DIGESTIVE DISEASES
- Immune checkpoint blockade in hepatocellular carcinoma: Current progress and future directions
- (2014) Tai Hato et al. HEPATOLOGY
- Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of Sorafenib
- (2014) Andrew X. Zhu et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- How to STATE suitability and START transarterial chemoembolization in patients with intermediate stage hepatocellular carcinoma
- (2014) Florian Hucke et al. JOURNAL OF HEPATOLOGY
- Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib
- (2014) Maria Reig et al. JOURNAL OF HEPATOLOGY
- Pretreatment MicroRNA Level and Outcome in Sorafenib-treated Hepatocellular Carcinoma
- (2014) Benedek Gyöngyösi et al. JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY
- MicroRNA-425-3p predicts response to sorafenib therapy in patients with hepatocellular carcinoma
- (2014) Valentina Vaira et al. LIVER INTERNATIONAL
- Cancer biomarkers: Written in blood
- (2014) Ed Yong NATURE
- Treatment of intermediate-stage hepatocellular carcinoma
- (2014) Alejandro Forner et al. Nature Reviews Clinical Oncology
- First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
- (2014) Benjamin J. Solomon et al. NEW ENGLAND JOURNAL OF MEDICINE
- A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancer
- (2013) L. Kadalayil et al. ANNALS OF ONCOLOGY
- Changes in plasma vascular endothelial growth factor at 8 weeks after sorafenib administration as predictors of survival for advanced hepatocellular carcinoma
- (2013) Kaoru Tsuchiya et al. CANCER
- Postprogression survival of patients with advanced hepatocellular carcinoma: Rationale for second-line trial design
- (2013) Maria Reig et al. HEPATOLOGY
- The ART of decision making: Retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma
- (2013) Wolfgang Sieghart et al. HEPATOLOGY
- Immunodominance and functional alterations of tumor-associated antigen-specific CD8+T-cell responses in hepatocellular carcinoma
- (2013) Tobias Flecken et al. HEPATOLOGY
- Differential effects of sorafenib on liver versus tumor fibrosis mediated by stromal-derived factor 1 alpha/C-X-C receptor type 4 axis and myeloid differentiation antigen-positive myeloid cell infiltration in mice
- (2013) Yunching Chen et al. HEPATOLOGY
- Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study
- (2013) Philip J. Johnson et al. JOURNAL OF CLINICAL ONCOLOGY
- Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study
- (2013) Josep M. Llovet et al. JOURNAL OF CLINICAL ONCOLOGY
- Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial
- (2013) Ann-Lii Cheng et al. JOURNAL OF CLINICAL ONCOLOGY
- A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C
- (2013) Bruno Sangro et al. JOURNAL OF HEPATOLOGY
- The ART-strategy: Sequential assessment of the ART score predicts outcome of patients with hepatocellular carcinoma re-treated with TACE
- (2013) Florian Hucke et al. JOURNAL OF HEPATOLOGY
- Plasma Biomarkers as Predictors of Outcome in Patients with Advanced Hepatocellular Carcinoma
- (2012) J. M. Llovet et al. CLINICAL CANCER RESEARCH
- Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma
- (2012) Nicola Personeni et al. JOURNAL OF HEPATOLOGY
- Diagnostic and therapeutic potential of miRNA signatures in patients with hepatocellular carcinoma
- (2012) Florie Borel et al. JOURNAL OF HEPATOLOGY
- Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study
- (2012) Armando Santoro et al. LANCET ONCOLOGY
- Spontaneous regression of hepatocellular carcinoma is most often associated with tumour hypoxia or a systemic inflammatory response
- (2012) Jonathan I. Huz et al. HPB
- The effects of sorafenib on the portal hypertensive syndrome in patients with liver cirrhosis and hepatocellular carcinoma - a pilot study
- (2011) M. Pinter et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Safety and efficacy of sorafenib in hepatocellular carcinoma: the impact of the Child-Pugh score
- (2011) A. Hollebecque et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib
- (2011) M. Pinter et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma
- (2011) Masatoshi Kudo et al. EUROPEAN JOURNAL OF CANCER
- Fighting the bushfire in HCC trials
- (2011) Peter Schirmacher et al. JOURNAL OF HEPATOLOGY
- Treatment of Non–Small-Cell Lung Cancer with Erlotinib or Gefitinib
- (2011) Vince D. Cataldo et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Significance of Early Alpha-Fetoprotein Level Changes in Predicting Clinical and Survival Benefits in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib
- (2011) T. Yau et al. ONCOLOGIST
- Reversible Decrease of Portal Venous Flow in Cirrhotic Patients: A Positive Side Effect of Sorafenib
- (2011) Romain Coriat et al. PLoS One
- Clinical characteristics of patients with hepatocellular carcinoma in Austria – is there a need for a structured screening program?
- (2011) Florian Hucke et al. WIENER KLINISCHE WOCHENSCHRIFT
- Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma
- (2010) Yu-Yun Shao et al. CANCER
- Sorafenib attenuates the portal hypertensive syndrome in partial portal vein ligated rats
- (2009) Thomas Reiberger et al. JOURNAL OF HEPATOLOGY
- Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
- (2009) Eric Van Cutsem et al. NEW ENGLAND JOURNAL OF MEDICINE
- TGF-β: A Master of All T Cell Trades
- (2008) Ming O. Li et al. CELL
- Pivotal Role of mTOR Signaling in Hepatocellular Carcinoma
- (2008) Augusto Villanueva et al. GASTROENTEROLOGY
- Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. JNCI-Journal of the National Cancer Institute
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
- (2008) Ann-Lii Cheng et al. LANCET ONCOLOGY
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now